Cena Research Institute: Full-scope cardiovascular research across therapeutics, devices, diagnostics, and AI. A trial site and full-service CRO, based in Houston. We run sponsor protocols, validate new technology, and develop our own IP. Real-world data, regulatory-grade evidence, faster answers.
A trial site and full-service CRO, based in Houston.
We run sponsor protocols, validate new technology, and develop our own IP. Real-world data, regulatory-grade evidence, faster answers.
About CRI
Founded in 2014, Cena Research Institute (CRI) is a Houston-based cardiovascular research organization operating across the full research lifecycle. We serve as a clinical trial site for pharmaceutical and device sponsors, provide full-service CRO support for teams running their own protocols, and develop original diagnostics and technology in-house.
Our work spans therapeutics, devices, diagnostics, and AI, grounded in one of the country’s most representative patient populations and held to regulatory-grade standards. The result: real-world evidence and faster, more reliable answers for the partners building the future of cardiovascular care.
What We Do
A ready cardiovascular site for Phase II–IV pharmaceutical and device trials, with fast activation and reliable enrollment.
End-to-end support for teams running their own protocols: design, execution, monitoring, and close-out.
Independent clinical validation of cardiovascular devices and diagnostics against regulatory-grade endpoints.
Real-world validation of AI algorithms, remote monitoring, and digital health platforms.
Original research and technology developed in-house, from concept to publication.
IRB management, independent monitoring, rigorous analysis, and peer-reviewed dissemination built to sponsor and FDA standards.
By the Numbers
12+
Studies Conducted
1,500+
Patients Enrolled
7
Active Sponsors
~2 wks
Avg. Site Activation
15+
Publications & Abstracts
Selected Clinical Research Experience
International, randomized, sham‑controlled clinical trial evaluating alcohol‑mediated renal denervation. Results published in a peer‑reviewed cardiovascular journal.
Phase III outcomes trial evaluating abelacimab in patients with atrial fibrillation at high risk for stroke.
Large‑scale biometric validation studies across hypertensive and hypotensive populations.
Clinical investigations in heart failure, post‑transplant physiology, postural orthostatic tachycardia syndrome, and cognitive outcomes.
Peer‑Reviewed Research & Thought Leadership
CRI investigators contribute to peer‑reviewed literature and scientific discourse across cardiovascular medicine, artificial intelligence, and digital health.
Publications reflect independent scholarly work by CRI investigators. Journal appearance does not imply organizational endorsement.
Community & Events
Lone Star HealthTech AI Summit
Hosted by Cena Research Institute and Modi Ventures, and run with our student volunteers through the Cena Research Foundation.
